Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.81 -0.37 (-0.77%)

Streaming Delayed Price Updated: 3:10 PM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

41 42 Next >

Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales

May 05, 2023

Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.

Via MarketBeat

7 Blue-Chip Stocks to Buy in May 2023 ↗

May 04, 2023

While not the most exciting sector available, rising fears in the market incentivizes the best blue-chip stocks to buy.

Via InvestorPlace

Why Regeneron Pharmaceuticals Shares Are Trading Lower Today ↗

May 04, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating

Via Benzinga

7 Stock Upgrades and Downgrades Alerts You Cannot Ignore ↗

May 04, 2023

Analyst stock upgrades and downgrades caught the market's attention in the last week and putting investors on notice for buys and sells.

Via InvestorPlace

First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories ↗

May 01, 2023

Benzinga

Via Benzinga

Sanofi (SNY) Q1 2023 Earnings Call Transcript ↗

April 28, 2023

SNY earnings call for the period ending March 31, 2023.

Via The Motley Fool

European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals ↗

May 01, 2023

The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public...

Via Benzinga

Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront ↗

May 01, 2023

Maze Therapeutics has signed an exclusive worldwide license agreement with Sanofi SA (NASDAQ: SNY) for Maze's glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is currently...

Via Benzinga

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗

April 28, 2023

Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.

Via Investor's Business Daily

Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales ↗

April 27, 2023

French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in

Via Benzinga

Sanofi (NASDAQ: SNY) Records 52-Week High Wednesday Morning

April 26, 2023

Via Investor Brand Network

Earnings Outlook For Sanofi ↗

April 26, 2023

Via Benzinga

Sanofi (NASDAQ: SNY) Sets New 52-Week High in Tuesday Session

April 25, 2023

Via Investor Brand Network

Sanofi (NASDAQ: SNY) Climbs to New 52-Week High

April 21, 2023

Via Investor Brand Network

Earnings Scheduled For April 27, 2023 ↗

April 27, 2023

Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter.

Via Benzinga

AbbVie Stock Shows Improved Relative Price Strength ↗

April 13, 2023

AbbVie stock had its Relative Strength Rating upgraded from 69 to 76 Thursday, but still shy of the 80 or higher score you prefer to see.

Via Investor's Business Daily

US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet' ↗

April 27, 2023

Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher.

Via Benzinga

Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz ↗

April 24, 2023

Via Benzinga

United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review ↗

April 21, 2023

The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.

Via Benzinga

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗

April 19, 2023

Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...

Via Benzinga

Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So ↗

April 18, 2023

On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.

Via Benzinga

3 Healthcare Dividend Payers With Big Price Growth

April 14, 2023

Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers.

Via MarketBeat

Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise ↗

April 12, 2023

Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies...

Via Benzinga

Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information ↗

April 11, 2023

Via Benzinga

Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow ↗

April 11, 2023

A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global...

Via Benzinga

Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens ↗

April 10, 2023

Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday

Via Investor's Business Daily

2 Top Healthcare Stocks Defying the Bear Market ↗

April 07, 2023

The market sell-off over the past year hasn't stopped these healthcare giants from rallying.

Via The Motley Fool

Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market ↗

April 06, 2023

Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years.

Via The Motley Fool

Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity? ↗

March 30, 2023

Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease.

Via The Motley Fool

Zoetis Stock Sees IBD Relative Strength Rating Improve To 73 ↗

March 27, 2023

Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for.

Via Investor's Business Daily

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.